Who are estradiol plus progesterone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Transdermal estrogen, estradiol and progesterone, Estradiol/norethindrone acetate, Estracomb TTS, Estradiol+MPA, Femoston® 1, Femoston® 2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/estradiol-plus-progesterone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

estradiol plus progesterone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

estradiol plus progesterone (estradiol plus progesterone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy (HRT). Area: Endocrinology / Women's Health.

marketed Hormone replacement therapy (HRT) Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR) Endocrinology / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

estradiol plus progesterone (estradiol plus progesterone) — Peking Union Medical College Hospital. Estradiol and progesterone together provide hormone replacement therapy by restoring circulating levels of endogenous female sex hormones.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
estradiol plus progesterone TARGET	estradiol plus progesterone	Peking Union Medical College Hospital	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
Transdermal estrogen	Transdermal estrogen	University of Utah	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
estradiol and progesterone	estradiol and progesterone	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
Estradiol/norethindrone acetate	Estradiol/norethindrone acetate	Myovant Sciences GmbH	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha and beta; progesterone receptor
Estracomb TTS	Estracomb TTS	Anna Posadzy-Małaczyńska	marketed	Hormone replacement therapy (HRT)	Estrogen receptor (ER-α, ER-β) and progesterone receptor (PR)
Estradiol+MPA	Estradiol+MPA	Brigham and Women's Hospital	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha and beta; progesterone receptor
Femoston® 1, Femoston® 2	Femoston® 1, Femoston® 2	Scientific Research Institute of Public Health, Russian Federation	marketed	Hormone replacement therapy (HRT)	Estrogen receptor (ER-α, ER-β) and progesterone receptor (PR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy (HRT) class)

Anna Posadzy-Małaczyńska · 1 drug in this class
Beni-Suef University · 1 drug in this class
Brigham and Women's Hospital · 1 drug in this class
El Shatby University Hospital for Obstetrics and Gynecology · 1 drug in this class
Erasmus Medical Center · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
Myovant Sciences GmbH · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
Scientific Research Institute of Public Health, Russian Federation · 1 drug in this class
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). estradiol plus progesterone — Competitive Intelligence Brief. https://druglandscape.com/ci/estradiol-plus-progesterone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing